﻿<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Explor Med</journal-id>
<journal-id journal-id-type="publisher-id">EM</journal-id>
<journal-title-group>
<journal-title>Exploration of Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2692-3106</issn>
<publisher>
<publisher-name>Open Exploration Publishing</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.37349/emed.2025.1001358</article-id>
<article-id pub-id-type="manuscript">1001358</article-id>
<article-categories>
<subj-group>
<subject>Correction</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Correction: Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9984-7468</contrib-id>
<name>
<surname>Sato</surname>
<given-names>Yoshiharu</given-names>
</name>
<xref ref-type="aff" rid="I1" />
<xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">DNA Chip Research Inc., Kawasaki 3-1200, Japan</aff>
<author-notes>
<corresp id="cor1">
<bold>*Correspondence:</bold> Yoshiharu Sato, DNA Chip Research Inc., Shinmaruko-Higashi, Nakahara-ku, Kawasaki 3-1200, Japan. <email>yo-sato@dna-chip.co.jp</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>09</month>
<year>2025</year>
</pub-date>
<volume>6</volume>
<elocation-id>1001358</elocation-id>
<permissions>
<copyright-statement>© The Author(s) 2025.</copyright-statement>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.37349/emed.2025.1001349" ext-link-type="doi">Correction to “<article-title>Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges</article-title>” by Sato Y. Explor Med. 2025;6:1001349. DOI: <ext-link xlink:href="https://doi.org/10.37349/emed.2025.1001349" ext-link-type="uri">10.37349/emed.2025.1001349</ext-link></related-article>
</article-meta>
</front>
<body>
<p id="p-1">In the recently published review article, an error was identified in the description of the BR.31 trial (in the section “Ongoing prospective NSCLC MRD studies”). The article incorrectly stated that “The BR.31 trial (NCT02273375) is evaluating the efficacy of atezolizumab (anti-PD-L1) compared to placebo in patients with stage IB–IIIA NSCLC following surgical resection”. The correct statement is that “The BR.31 trial (NCT02273375) is evaluating the efficacy of durvalumab (anti-PD-L1) compared to placebo in patients with stage IB–IIIA NSCLC following surgical resection”. The author sincerely apologizes for this error and any confusion it may have caused to readers and the research community. This has now been amended in the HTML and PDF versions of the article.</p>
<p id="p-2">The original uncorrected PDF can be accessed from <uri xlink:href="https://www.explorationpub.com/uploads/er1001349.pdf">https://www.explorationpub.com/uploads/er1001349.pdf</uri></p>
</body>
</article>